Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
Clinical and Molecular Hepatology
;
: 74-79, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-165806
ABSTRACT
BACKGROUND/AIMS:
Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been used to treat chronic hepatitis C without severe adverse effects and have achieved a sustained viral response (SVR) rate of 80-90% with short treatment duration. We were interested to determine whether all patients who failed to respond to or were ineligible for interferon-based therapy could be treated with DAAs.METHODS:
Medical records of patients with positive serum anti-hepatitis C virus (HCV) or HCV RNA between January 2009 and December 2013 were reviewed. Demographic, clinical, and treatment data were collected for analysis.RESULTS:
A total of 876 patients were positive for both anti-HCV and HCV RNA. Of these, 244 patients were eligible for interferon, although this was associated with relapse in 39 (16%) of patients. In total, 130 patients stopped interferon therapy (67% adverse effects, 28% non-adherent, 4% malignancy, 1% alcohol abuse) and 502 patients were ineligible (66% medical contraindications, 25% non-adherent, 5% socioeconomic problems). Among 671 patients who were ineligible for or failed to respond to interferon therapy, more than 186 (27.7%) could not be treated with DAA due to financial, social, or cancer-related conditions.CONCLUSIONS:
Newly developed DAAs are a promising treatment for patients with chronic hepatitis C who are ineligible for or failed to respond to interferon-based therapy. Nevertheless, not all chronic hepatitis C patients can be treated with DAAs due to various reasons.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Recurrencia
/
ARN
/
Registros Médicos
/
Interferones
/
Hepatitis C
/
Hepatitis C Crónica
Límite:
Humanos
Idioma:
Inglés
Revista:
Clinical and Molecular Hepatology
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS